Technological advances in both siRNA (small interfering RNA) and whole genome sequencing have demonstrated great potential in translating genetic information into siRNA-based drugs to halt the synthesis of most disease-causing proteins. Despite its powerful promises as a drug, siRNA requires a sophisticated delivery vehicle because of its rapid degradation in the circulation, inefficient accumulation in target tissues and inability to cross cell membranes to access the cytoplasm where it functions. Lipid nanoparticle (LNP) containing ionizable amino lipids is the leading delivery technology for siRNA, with five products in clinical trials and more in the pipeline. Here, we focus on the technological advances behind these potent systems for ...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
Lipid nanoparticles (LNPs) are an emerging vehicle for gene delivery that accommodate both nucleic a...
\u3cp\u3eConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to ...
\u3cp\u3eGenetic drugs based on RNA or DNA have remarkable therapeutic potential as virtually any di...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
Genetic drugs based on RNA or DNA have remarkable therapeutic potential as virtually any disease can...
Genetic drugs based on RNA or DNA have remarkable therapeutic potential as virtually any disease can...
Mantle cell lymphoma (MCL) is an extremely difficult to treat subtype of non-Hodgkin lymphoma (NHL) ...
Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the deli...
RNA interference has been proven to be a powerful tool for gene probing and has also great therapeut...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
Small interfering RNAs (siRNAs) indicate the unprecedented versatility in silencing disease-causing ...
Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the deli...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
Lipid nanoparticles (LNPs) are an emerging vehicle for gene delivery that accommodate both nucleic a...
\u3cp\u3eConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to ...
\u3cp\u3eGenetic drugs based on RNA or DNA have remarkable therapeutic potential as virtually any di...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
Genetic drugs based on RNA or DNA have remarkable therapeutic potential as virtually any disease can...
Genetic drugs based on RNA or DNA have remarkable therapeutic potential as virtually any disease can...
Mantle cell lymphoma (MCL) is an extremely difficult to treat subtype of non-Hodgkin lymphoma (NHL) ...
Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the deli...
RNA interference has been proven to be a powerful tool for gene probing and has also great therapeut...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
Small interfering RNAs (siRNAs) indicate the unprecedented versatility in silencing disease-causing ...
Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the deli...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
ConspectusDelivering nucleic acid-based therapeutics to cells is an attractive approach to target th...
Lipid nanoparticles (LNPs) are an emerging vehicle for gene delivery that accommodate both nucleic a...